What Liquid Cartilage™ actually is

Two names circulate for the same treatment, which causes understandable confusion at the research stage. Liquid Cartilage™ is the procedure name used by MSK Doctors and Lincolnshire Hip. The product itself is ChondroFiller™, a CE-marked Class III medical device manufactured by Meidrix Biomedicals GmbH in Germany. Knowing both names makes it easier to cross-reference clinical information and ask informed questions at consultation.

ChondroFiller™ is a cell-free Type I collagen solution — the same structural protein found naturally in cartilage and connective tissue. When injected into the hip joint under ultrasound guidance, it self-gels within minutes to form a stable three-dimensional scaffold over the area of focal cartilage damage. The mechanism is called acellular matrix-induced chondrogenesis: the scaffold draws the patient's own progenitor cells in from the surrounding synovium and subchondral bone, providing a framework within which those cells can build new tissue. As that host tissue matures, the collagen scaffold is gradually resorbed.

This is not a lubricating injection. Hyaluronic acid works by supplementing joint fluid and is cleared from the joint within weeks. ChondroFiller™ is also distinct from permanent synthetic gels: it is a biological material the body can populate, integrate, and remodel — supporting the patient's own repair processes rather than replacing them. The entire treatment is delivered as an outpatient appointment under local anaesthetic, with no general anaesthesia and no surgical incision.

Which hip patients are most likely to be suitable

The most common question patients ask at this stage is whether their hip has already gone too far. The answer is often more encouraging than they expect.

ChondroFiller™ targets focal cartilage defects — areas of Grade III or IV damage that are localised rather than affecting the entire joint surface. A hip that has worn evenly across every surface into end-stage osteoarthritis sits outside this treatment's scope. A hip with a defined patch of deeper cartilage loss — even one described as 'bone on bone' in that zone — may still be assessable. Being 'bone on bone' in one compartment does not automatically rule a patient out. Patients presenting with femoroacetabular impingement (FAI) alongside cartilage damage are also within the scope of published evidence, including Perez-Carro et al. (2021), and are regularly assessed. There is no upper age limit.

The Lincolnshire Hip online suitability checker — which uses four assessment lenses (physics, chemistry, biology, and timing) — gives patients a structured indication before they book. In broad terms, physics relates to joint mechanics and defect geometry; chemistry to the biological environment within the joint; biology to the patient's own capacity for tissue repair; and timing to how far the damage has progressed and what treatment window remains. Together the four lenses build a rounded initial picture rather than a binary pass or fail.

No GP referral is needed to complete the checker or to book a consultation at the Grantham or Sleaford clinics. The assessment explores whether the pattern of damage is compatible with the ChondroFiller pathway — individual suitability is confirmed at consultation.

Where to access Liquid Cartilage™ in Lincolnshire

Both clinic sites — Grantham (NG31) and Sleaford (NG34) — are run by Professor Paul Y. F. Lee, who founded London Cartilage Clinic at 66 Harley Street and established it as the first UK centre to offer ChondroFiller™ as an outpatient injection. Patients from across the East Midlands and the wider non-London catchment can therefore access the same clinical expertise and treatment pathway without travelling to the capital.

The practical first step is the Lincolnshire Hip online suitability checker, a structured assessment patients can complete before committing to an appointment. Those ready to proceed can book a consultation directly — no GP letter is needed at either site. That initial appointment brings together a clinical case review and an ultrasound assessment to confirm whether the pattern of cartilage damage suits the ChondroFiller injection pathway before any treatment decision is made.

Lincolnshire Hip is part of the MSK Doctors group; clinic locations, the suitability checker, and contact details are available through the Lincolnshire Hip website.

What happens at your appointment

Arriving for a Liquid Cartilage™ appointment, patients check in to the outpatient clinic — either in Grantham or Sleaford — and go straight into a structured consultation. The treating clinician reviews the imaging and case history, confirms the treatment plan, and answers any remaining questions before anything else happens.

Next comes a targeted ultrasound scan. This is used to map the anatomy of the hip and to plan exactly where the needle needs to be placed. When the injection itself begins, the clinician uses live ultrasound imaging to guide the needle in real time to the correct position within the joint — no incision, no surgical portal, and no general anaesthetic. A local anaesthetic is used to keep the procedure comfortable. Intravenous antibiotic cover is given as part of the appointment to reduce infection risk.

The ChondroFiller™ collagen solution is then delivered into the hip joint under that continuous image guidance. As described in the overview section above, it gels in situ within minutes — the biological repair process then takes over in the weeks that follow.

Once the injection is complete, there is no overnight hospital stay. Patients leave the clinic the same day. Specific recovery guidance is provided at the appointment itself, tailored to each patient's presentation; this is not a post-surgical recovery and should not be treated as one.

A six-week follow-up appointment is included in the package. At that review, the clinical team assesses early response, answers any questions about progress, and discusses next steps if needed. The whole appointment bundle — consultation, scan, product, injection, antibiotic cover, and follow-up — is covered within the quoted treatment cost.

Cost and NHS funding

Liquid Cartilage™ hip injection is available only as a self-funded private treatment. As of mid-2026, NICE has not approved ChondroFiller™ for routine NHS commissioning, and no Integrated Care Board in England — including Lincolnshire's — funds it. The NHS hip pathway moves patients from conservative management directly to total hip replacement, leaving no funded route for cartilage-preservation biologics in between.

This absence of NHS funding reflects a structural commissioning lag that applies to Class III regenerative devices rather than any clinical rejection of the product itself. ChondroFiller™ has held CE-marking since 2013 and has been in active private clinical use across the UK throughout that period.

Pricing in the UK ranges from approximately £3,000 for a single box (suited to smaller focal defects) up to £8,000–£9,800 for three boxes (larger defects). The volume required is determined at clinical assessment based on defect size. Importantly, these figures cover the all-inclusive appointment bundle described in the section above — there are no hidden consultation fees or add-on charges for the scan, antibiotic cover, or follow-up.

Major UK private medical insurers, including Bupa and AXA, do not routinely cover ChondroFiller™ for hip cartilage repair. Individual policies vary, so patients are advised to check their own cover directly with their insurer before booking. Where a policy allows independent claims submission, itemised invoices can be provided on request.

What the clinical evidence currently shows

Hip patients studied in published series have shown a modified Harris Hip Score improvement of approximately +33 points following ChondroFiller™ treatment — a clinically meaningful functional gain. MRI assessment using MOCART scoring, which measures the structural quality of tissue within treated defects, has returned scores of 70–87, indicating measurable scaffold integration and tissue regeneration at the repair site.

More than 19,000–20,000 cases have been performed globally across more than a decade of clinical use. Hip-specific published evidence includes Perez-Carro et al. (2021), which examined ChondroFiller™ use in focal cartilage defects associated with femoroacetabular impingement (FAI). Across that global case volume, the adverse event rate sits at approximately 0.06% — a low signal for a CE-marked Class III biological device.

The most mature randomised trial evidence comes from the knee. A dedicated randomised controlled trial in the hip joint specifically has not yet been published, and that is worth stating plainly. The hip outcome data available — functional scores, MOCART imaging, and a large real-world case series — support cautious clinical confidence in appropriate candidates, but they do not yet carry the evidential weight that a multi-centre RCT would provide.

For patients trying to weigh this up practically: the published numbers are real, the device has been in active clinical use since 2013, and the hip evidence base is growing — but a clinician-led assessment remains the right place to map that evidence against an individual's specific defect, activity level, and expectations.